StemCell Therapy

Contact Information

Available for logged-in reporters only

Newswise March 7, 2014, Phoenix, AZ -- Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans. Recent developments in stem cell research have made it possible to assess its effect on intervertebral disc (IVD) height, Mayo Clinic researchers reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.

This landmark study draws the conclusion in pre-clinical animal studies that stem cell therapy for disc degenerative disease might be a potentially effective treatment for the very common condition that affects peoples quality of life and productivity, said the senior author, Wenchun Qu, MD, PhD, of the Mayo Clinic in Rochester, Minn.

Dr. Qu said not only did disc height increase, but stem cell transplant also increased disc water content and improved appropriate gene expression. These exciting developments place us in a position to prepare for translation of stem cell therapy for degenerative disc disease into clinical trials, he said.

The increase in disc height was due to restoration in the transplant group of the nucleus pulposus structure, which refers to the jelly-like substance in the disc, and an increased amount of water content, which is critical for the appropriate function of the disc as a cushion for the spinal column, the researchers concluded.

The researchers performed a literature search of MEDLINE, EMBASE and PsycINFO databases and also manually searched reference lists for original, randomized, controlled trials on animals that examined the association between IVD stem cell transplant and the change of disc height. Six studies met inclusion criteria. Differences between the studies necessitated the use of random-effects models to pool estimates of effect.

What they found was an over 23.6% increase in the disc height index in the transplant group compared with the placebo group (95% confidence interval [CI], 19.7-23.5; p<0.001). None of the 6 studies showed a decrease of the disc height index in the transplant group. Increases in the disc height index were statistically significant in all individual studies.

The authors commented that it is time to turn attention to the much-needed work of determining the safety, feasibility, efficacy of IVD stem cell transplant for humans.

A hallmark of IVD degenerative disease is its poor self-repair capacity secondary to the loss of IVD cells. However, current available treatments fail to address the loss of cells and cellular functions. In fact, many invasive treatments further damage the disc, causing further degeneration in the diseased level or adjacent levels, said the lead study author Jason Dauffenbach, DO. The goal of tissue engineering using stem cells is to restore the normal function and motion of the diseased human spine.

Original post:
Stem Cell Transplant Shows "Landmark" Promise for Treatment of Degenerative Disc Disease: Mayo Clinic

21.Spinal Cord Injury(T5-6) Treated by Stem Cell Therapy(After)
After treatment: The patient received four times of stem cell treatment in our center. His overall condition improved a lot after the treatment. The injury l...

By: Cells Center China

See the rest here:
21.Spinal Cord Injury(T5-6) Treated by Stem Cell Therapy(After) - Video

Google stem cell therapy and a whole host of results show up. Stem cell therapy for hair loss, diabetes, cancer and practically everything else. It is touted as the medicine of hope, the panacea for all ills.

But to ensure that this potentially-powerful technology is not misused in the country, the Indian Council of Medical Research has come up with a set of guidelines to regulate their use.

Under the new guidelines, any use of stem cells in patients will be considered research, not therapy.

This means stem cells can now only be used on patients within the purview of an approved, and monitored clinical trial anything outside of this would be considered malpractice. Ananthram Shetty, professor of minimally-invasive surgery at Canterbury Christ Church University, UK, said the guidelines are much-needed, welcome move in the right direction.

Prof. Shetty, who has been working with stem-cell technology for 27 years, and is often in India to demonstrate their use in research surgeries, said this would prevent anybody and everybody from claiming unproven benefits. Lots of people dont really understand what stem cells are. And those who have a terminal illness are willing to try anything. There are some people who use this to raise false hopes. And this is what the guidelines seek to stop, he said.

J.S. Rajkumar, chairman, Lifeline Hospital, however, said the guidelines could have been clearer about the use of adult stem cells over embryonic stem cells, he said. Now, the procedures involved and the time it would take could dissuade many, he said, while there is a real need for funds to be pumped in for research into this technology.

Another International Ear Care Day passed by on March 3.

It spelled out a clear message ear care can avoid hearing loss.

But the question is how many people know how to take care of their ears. What is interesting is the ear is a self-cleaning organ and does not require any kind of cleaning. But many clean their ears using safety pins, hair pins and even matchsticks.

While doctors advise against the use of such objects, they discourage the use of cotton buds too. Some heat coconut oil and pour into the ears. This could cause fungal infections. The ear drum is very thin and can be damaged, leading to loss of hearing, said M. Ramaniraj, professor of ENT, Government Stanley Medical College Hospital.

Read this article:
Guidelines on use of stem cell therapy

Celltex Therapeutics of Houston ceased treatment patients in the U.S. last year after a warning from regulators, and will now send patients for treatments to Mexico

Flickr/GE Healthcare

US citizens who had pinned their hopes on a company being able to offer stem-cell treatments close to home will now need to travel a little farther. Celltex Therapeutics of Houston, Texas, stopped treating patients in the United States last year following a warning from regulators. A 25 January e-mail to Celltex customers indicates that the firm will now follow in the footsteps of many other companies offering unproven stem-cell therapies and send its patients abroad for treatment but only to Mexico.

The stem-cell treatments offered by Celltex involved extracting adult stem cells from a patient, culturing them and then reinjecting them in a bid to replenish damaged tissue. It had been offering the treatment for more than a year with one of its high-profile customers being Texas governor, Rick Perry when the US Food and Drug Administration (FDA) wrote to the company on 24 September 2012 advising it that the stem cells it harvested and grew were more than minimally manipulated during Celltex's procedures. As such, the FDA regarded the cells as drugs, which would require the agency's approval to be used in treatments. The FDA also warned that Celltex had failed to address problems in its cell processing that inspectors from the agency had identified in an April 2012 inspection of its cell bank in Sugar Land, Texas. Shortly after it received the letter, Celltex stopped injecting stem cells into patients.

For customers who still had cells banked at Celltex and were wondering how to get them out, things became more chaotic when Celltex and RNL Bio, a company based in Seoul, South Korea, which operated the processing center and bank in Sugar Land, sued each other over financial disagreements. Celltex had to issue a restraining order just to gain access to the cells.

The January e-mail from Celltex reassures customers that their cells are safely stored in a facility in Houston and adds: We anticipate that we will be able to offer our stem cell therapy services to physicians in Mexico starting very soon! The e-mail also says that the company is building a new laboratory in Houston, to be opened in March.

Celltex adds that it will carry out an FDA-approved clinical trial, to start shortly after a March meeting with the FDA, pending a positive review from the regulator. However, the company had said in a 25 October e-mail to patients that it would start such a trial within two months and that patient enrolment could begin in late November.

Leigh Turner, a bioethicist at the University of Minnesota in Minneapolis, says that the move to Mexico is "not surprising", given the companys difficulties in the United States.

As Celltex's stem culturing and banking technology was licensed from RNL Bio, it is also not clear whether it has the expertise needed to launch a clinical trial on its own, says Turner. "It would have to build a stem-cell company from the ground floor up. I wouldnt say it is anywhere near the starting line."

Celltex did not respond to questions about how it would ship stem cells to Mexico or how it would perform the clinical research needed to seek FDA approval.

Go here to read the rest:
Controversial Stem Cell Company Moves Treatment out of U.S.

stem cell therapy treatment for Cerebral Palsy with Mental Retardation by dr alok sharma, mumbai
improvement seen in just 5 daysafter stem cell therapy treatment for Cerebral Palsy with Mental Retardation by dr alok sharma, mumbai, india. Stem Cell Thera...

By: Neurogen Brain and Spine Institute

Read the original:
stem cell therapy treatment for Cerebral Palsy with Mental Retardation by dr alok sharma, mumbai - Video

Experience and expertise run in the genes of this doctor, a third-generation fresh cell therapy practitioner

It was a pleaseant, winter morning in Edenkoben, Germany and a group of 15 people from various countries such as Indonesia, the Philippines, Italy, and Germany congregated for breakfast in a coffee shop in this quaint city. Most of these people just flew in from their respective countries, or drove in from different European cities.

But they were not there for an international conference. They were all there for their shots of fresh cell from Dr. Robert Janson-Mueller.

For the past couple of years, through his solo practice, Dr. Robert Mueller has been sharing the benefits of fresh cell therapy with people who need to seek alternative means to remedy various diseases or chronic conditions of their body, or anti-aging solutions.

Although Filipinos has heard of stem cell therapy only in recent years, thanks to celebrities and politicians who have undergone the treatment and do swear by its efficacy, fresh cell therapy has been around since the 1930s.

The Swiss doctor Prof. Paul Niehans first injected cells originating from animal organs intramuscular into patients in 1931 and is thus considered the founder of live cell therapy. Dr. Robert Muellers grandfather, Dr. Philipp Janson, was one of the first doctors to introduce this method in Germany in 1949. His father, Dr. Wolfgang Janson-Meller, also extensively practiced for 35 years.

Since the 90s, I have been able to participate in the wealth of experience that my father, who is always available for help and advice, has gladly passed on to me. I have been using this method of treatment in my own practice since 2003, says Dr. Mueller.

However, the 47-year old doctor differentiates his practice from others (there are only five known doctors who do fresh cell therapy in Germany) because his clinic tailor-fits the fresh cell injections according to the specific needs of the individuals body. A patient thus gets from about eight to 30 injections, depending on the needs.

In this interview with Dr. Mueller, the German expert sheds more light on this therapy that is attracting more and more Filipinos as an alternative treatment. He also explains why fresh cell therapy is not a cure-all or a miracle therapy, why cells from the sheep embryo is being used, why the treatment is becoming popular in Asia, and why it is not possible, up to now, that these therapies can be done in the Philippines.

For more information on fresh cell therapy, visit the website http://www.janson-mueller.de or call Joey Santos at 0917898-6564 or 633-8653.

Read the original here:
Cracking the fresh cell code

Orange County, CA (PRWEB) March 03, 2014

The top stem cell treatment clinic in Southern California, Telehealth, is now offering several knee pain treatment options for avoiding joint replacement. The regenerative medicine treatments involve either platelet rich plasma therapy, bone marrow derived stem cell injections or blood derived stem cell treatment. Call for more information and scheduling call (888) 828-4575. The treatments may be completely or partially covered by insurance.

Although knee replacement procedures have been exceptionally successful for reducing one's pain and improving functional abilities, there are some risks associated with the procedure, along with the fact they are not meant to last forever. Unlike conventional nonoperative treatments, such as steroid injections, regenerative medicine treatments maintain the ability to repair and regenerate arthritic tissue as opposed to simply masking pain.

The Board Certified doctors at Telehealth have extensive experience and regenerative medicine therapies for degenerative arthritis of the knee. Stem cell therapy for arthritis has been shown in several small published studies to provide excellent pain relief and maintain cartilage in the knee.

All of the treatments provided are low-risk and outpatient. They involve blood or bone marrow from the patient him or herself, which reduces the risk profile even more.

Telehealth Medical Group has two locations in Southern California. One is right in Santa Ana, while the other is in Upland. Appointments are readily available. Call for more information and scheduling to (888) 828-4575.

The rest is here:
Southern California Stem Cell Clinic, Telehealth, Now Offering Several Knee Treatment Options to Avoid Joint Replacement

Stem Cell Therapy | Stem cells from osteoarthritis patients as good as controls?
http://wwwarthritistreatmentcenter.com Stem cells from patients with osteoarthritis are as good as normal controls Alwin Scharstuhl and colleagues, in an art...

By: Nathan Wei

Go here to read the rest:
Stem Cell Therapy | Stem cells from osteoarthritis patients as good as controls? - Video

Annie - Before and After Stem Cell Therapy
I created this video with the YouTube Video Editor (http://www.youtube.com/editor)

By: Stacey Ragsdale

Original post:
Annie - Before and After Stem Cell Therapy - Video

Annie - Before Stem Cell
Here are some REAL results from stem cell therapy. This is Annie before her stem cell therapy treatment.

By: Stacey Ragsdale

Read the original here:
Annie - Before Stem Cell - Video

New York, New York (PRWEB) February 26, 2014

Adler Footcare of Greater New York is offering an advanced treatment option for chronic foot problems like plantar fasciitis, as well as common foot problems like Osteoarthritis, Achilles tendonitis and torn soft tissue.

In the past these conditions have been treated by physical therapy or orthotic therapy, but the results have often been poor, leaving patients continuing to struggle with the pain. With stem cell replacement therapy, the treatment of these conditions is proving far more effective and long lasting than traditional treatments.

At Adler Footcare we use live birth stem cells which are introduced into the affected area. Stem cells are used by many physicians to treat a broad variety of conditions because of their ability to either replicate themselves, or change into the cell type that is needed to repair the tissue that has been damaged. When a patient comes in for stem cell therapy, the affected area is carefully measured so the stem cells can be delivered directly to the area that needs the treatment.

The Joint Commission accredited Podiatric OR of Midtown Manhattan housed within Adler Footcare is designed to facilitate advanced treatments such as Stem Cell Replacement Therapy to all their patients.

With stem cell treatment we are finding that patients heal much faster and are able to return to their normal activities much sooner than with traditional treatment options, said Dr. Darline Kulhan, podiatric surgeon at Adler Footcare. Recovery time depends on each individual patients medical diagnosis and overall general health.

Treatments using stem cells have been used by physicians for over 100 years. Stem Cell Replacement Therapy is covered by commercial insurance and Medicare, and is approved and regulated by the FDA. The product is tested and screened by medical professionals to eliminate the potential of any communicable diseases.

To learn more about Stem Cell Replacement Therapy or to schedule a consultation with a New York podiatrist at Adler Footcare, call (212) 704-4310 or visit http://www.mynycpodiatrist.com.

About Adler Footcare New York

Dr. Jeffrey L. Adler, Medical/Surgical Director and owner of Adler Footcare New York has been practicing podiatric medicine since 1979 and has performed thousands of foot and ankle surgeries. Dr. Adler is board certified in Podiatric Surgery and Primary Podiatric Medicine by the American Board of Multiple Specialties in Podiatry. Dr. Adler is also a Professor of Minimally Invasive Foot Surgery for the Academy of Ambulatory Foot and Ankle Surgeons. As one of only several in the country who perform minimally invasive podiatric surgery, Dr. Adlers patients enjoy significantly reduced recovery times.

Continue reading here:
Stem Cell Replacement Therapy for Common Foot Injuries Provides Rapid Healing

Freeport, The Bahamas (PRWEB) February 21, 2014

Okyanos Heart Institute, whose mission it is to bring a new standard of care and a better quality of life to patients with coronary artery disease using adult stem cell therapy, announces CEO Matt Feshbach will present at the STEMSO Conference. He will join a panel to discuss the opportunities available through the new stem cell research and Therapy Act. The conference will be held at the Grand Lucayan Resort in Freeport, Grand Bahamas, February 19-22, 2014. The panel discussion will be Friday, February 21 from 8:45 9:45 a.m.

The conference, titled Bridging the Gap: Research to Point of Care, brings together medical scientists, clinicians, regulatory experts, and investors to discuss progress in the field of research and clinical protocols and the process of taking promising therapies to fight chronic disease to market in a responsible manner.

Friday opening remarks will be delivered by Ian Rolle, President of Grand Bahama Port Authority from 8:30 a.m. to 8:45 a.m. followed by the panel presentation until 9:45 a.m. which, in addition to Rolle will include Feshbach, Mitchell Fuerst, Esq., managing partner, Fuerst, Ittleman, David and Joseph. The panel will be moderated by Arthur K. Parris, Jr. of Parris Whittaker.

"With the passing of the Bahamas Stem Cell Research and Therapy Act, which requires high standards of patient safety and care, we believe the Bahamas is an ideal location to bring internationally-approved, adult stem cell technology to patients with unmet medical needs such as chronic coronary artery disease (CAD), says Feshbach. I am pleased to discuss the opportunities available in the Bahamas with investors, doctors and other stakeholders interested in making the Bahamas a world-class destination for adult stem cell therapy."

The STEMSO 2014 Conference in Freeport, Grand Bahama poses a unique opportunity for medical organizations which focus on adult stem cell-based medical treatments, states Douglas Hammond, president of STEMSO. This conference will provide companies looking to expand their research or clinical practices to offshore locations many good reasons to choose the Bahamas. Those attending will be able to network and view the most advanced research and clinical protocols utilizing autologous and allogeneic stem cells in the world today.

The complete agenda can be found on the organizations website at http://www.stemso.org. Other speakers include stem cell researchers, scientists and practitioners from around the world with leading discoveries in the field, and investors in the healthcare space.

Registration is open for attending and exhibiting on STEMSOs website.

ABOUT OKYANOS HEART INSTITUTE: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of rivers, symbolizes restoration of blood flow. For more information, go to http://www.okyanos.com/.

NEW MEDIA CONTENT: Okyanos LinkedIn Page: http://www.linkedin.com/company/okyanos-heart-institute Okyanos Facebook Page: https://www.facebook.com/OKYANOS Okyanos Twitter Page: https://twitter.com/#!/OkyanosHeart Okyanos Google+ Page: https://plus.google.com/+Okyanos/posts Okyanos You Tube Physician Channel: http://www.youtube.com/user/okyanosforphysicians

Link:
Okyanos Heart Institute CEO Matt Feshbach to Speak on Panel at International Stem Cell Society Global Conference

Stem Cell Treatment at "EmCell"
http://www.emcell.com/ Stem cell therapy is the rapidly developing area of modern medicine. Unique properties of fetal stem cells, the core of EmCell treatme...

By: Stem Cell Therapy Center "EMCELL"

Read the original here:
Stem Cell Treatment at "EmCell" - Video

A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Network's (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published in the Journal of Clinical Investigation quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly composed of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

About The Immune Tolerance Network

The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.

Story Source:

The above story is based on materials provided by Immune Tolerance Network. Note: Materials may be edited for content and length.

Read more here:
Deep TCR sequencing reveals extensive renewal of the T cell repertoire following autologous stem cell transplant in MS

Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Part 3: Regenerative Therapies: Prolotherapy, Platelet Rich Plasma (PRP) and Stem Cell Therapy Dr. David Wang, Harvard trained and Board Certified in Physica...

By: KaplanCenter

Read the rest here:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video

What is Stem Cell Therapy?
According to J. Peter Rubin, MD, Chair of the University of Pittsburgh #39;s Department of Plastic Surgery, stem cells are small cells that live within the tissu...

By: Smart Beauty Guide

See the rest here:
What is Stem Cell Therapy? - Video

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

The research, published online today in Nature is a significant leap in understanding the steps that a normal cell has to go through as it turns into AML, says Dr. Dick, and sets the stage to advance personalized cancer medicine by potentially identifying individuals who might benefit from targeting the pre-leukemic stem cell. AML is an aggressive blood cancer that the new research shows starts in stem cells in the bone marrow. Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network (UHN), and Professor in the Department of Molecular Genetics, University of Toronto, pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007).

"Our discovery lays the groundwork to detect and target the pre-leukemic stem cell and thereby potentially stop the disease at a very early stage when it may be more amenable to treatment," says Dr. Dick, who holds a Canada Research Chair in Stem Cell Biology and is also Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research (OICR).

"Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the pre-leukemic stem cell to prevent relapse," he says.

The findings show that in about 25% of AML patients, a mutation in the gene DNMT3a causes pre-leukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

The discovery of pre-leukemic stem cells came out of a large Leukemia Disease Team that Dr. Dick assembled and included oncologists who collected samples for the Princess Margaret Cancer Centre Biobank and genome scientists at the OICR who developed sophisticated targeted sequencing methodology. With this team, it was possible to carry out genomic analysis of more than 100 leukemia genes on many patient samples. The findings also capitalized on data from more than six years of experiments in Dr. Dick's lab involving growing human AML in special mice that do not reject human cells.

"By peering into the black box of how cancer develops during the months and years prior to when it is first diagnosed, we have demonstrated a unique finding. People tend to think relapse after remission means chemotherapy didn't kill all the cancer cells. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the pre-leukemic stem cells that can trigger another round of AML development and ultimately disease relapse," says Dr. Dick, who anticipates the findings will spawn accelerated drug development to specifically target DNMT3a.

These findings should also provide impetus for researchers to look for pre-cancerous cells in AML patients with other mutations and even in non-blood cancers.

Dr. Dick is also renowned for isolating a human blood stem cell in its purest form (2011) -- as a single stem cell capable of regenerating the entire blood system. He is a Senior Scientist at UHN's McEwen Centre for Regenerative Medicine and co-leader of a Cancer Stem Cell Consortium (CSCC)-funded research project HALT (Highly Active Anti-Leukemia Stem Cell Therapy), which is a partnership between CSCC and the California Institute for Regenerative Medicine.

For more than 20 years, Dr. Dick's research has focused on understanding the cellular processes that maintain tumour growth by investigating the complexities and interplay among genetic and non-genetic determinants of cancer. His research follows on the original 1961 discovery of the blood stem cell by Princess Margaret Cancer Centre (formerly Ontario Cancer Institute) scientists Dr. James Till and the late Dr. Ernest McCulloch, which formed the basis of all current stem cell research.

See the original post:
Cancer Researchers Discover Pre-Leukemic Stem Cell at Root of AML, Relapse

(PRWEB) February 11, 2014

The report Autologous Cell Therapy (ACT) Market (2012 - 2017), would be the first global and exclusive report on ACT market. It also gives clear information about the complete industry, approved products and potential market size; it also identifies driving and restraining factors for the global ACT market with analysis of trends, opportunities and challenges. The market is segmented and revenue is forecasted on the basis of major regions such as USA, Europe and Rest of the World (ROW). Further, market is segmented and revenues are forecasted on the basis of potential application areas of ACT.

Browse ACT market research data tables/figures spread through 111 slides and in-depth TOC on Autologous Cell Therapy Market". http://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html

Early buyers will receive 10% customization on this report @ http://www.marketsandmarkets.com/requestCustomization.asp?id=837.

The global market for ACT is valued around $650 million by 2011 with a CAGR of 21%. Several products and technologies of ACT are in pipeline which is expected to hit the market during the forecast period, which will result in increased growth rate.

There is a wide market potential and favorable landscape for adoption across many geographical locations of the world. During the forecast period, these technologies are expected to revolutionize the area of bio-pharma and personalized medicine. High incidence and lack of effective treatment for several diseases will drive the ACT technology in developed and developing nations.

Investment activities, for the past five years are actively held in research and developments, attracting interests of cell therapy industry firms, medical centers and academic institutions. ACT potential can be demonstrated by mergers, collaborations, acquisitions and partnerships that happened actively between the ACT technology developing companies in past three years. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.

Autologous Stem Cell and Non-Stem Cell Based treatments in North America are rapidly emerging as a major treatment for various incurable diseases such as Myocardial infarction, ischemic heart failure and diabetes.

Browse Related Reports: Global Transfection Technologies Market (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) (2012 2017) http://www.marketsandmarkets.com/Market-Reports/transfection-technologies-market-895.html

High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (uHTS), Label Free, Bioinformatics), by Apllications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018 http://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html

Read more:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Worth $2.2 Billion by 2017

MediVet Stem Cell Therapy For Pets
MediVet is the company that created the technology to use stem cell therapy to treat pets with arthritis and hip dysplasia.

By: Newman Veterinary Centers

View original post here:
MediVet Stem Cell Therapy For Pets - Video

Poway, CA (PRWEB) February 06, 2014

Stem Cell Therapy for Feline Kidney Disease is a special interest piece produced by Nicky Sims, the owner of Kitters, who recently had Vet-Stem Regenerative Cell Therapy for his Feline Kidney Disease. Nicky highlights Kitters journey through diagnosis of the disease and his recent stem cell therapy, as well as educating about stem cells and their benefits.

Nickys film explains that Kitters began showing signs of kidney failure at the age of 15, exhibiting classic symptoms; lack of appetite, excessive thirst, nausea and lethargy. In 2012, Kitters was officially diagnosed with Chronic Renal Failure, or kidney disease. He was prescribed a low protein diet and subcutaneous fluids for rehydration. This has been the standard treatment for decades although it has only been shown to slow the progression of the disease; not reverse it.

Dr. Richter at Montclair Veterinary Hospital thinks that there is something else that can help. In recent years, his hospital has begun using stem cells to treat animals for various orthopedic conditions such as pain from arthritis and dysplasia. In October 2013, Kitters would be the first cat he had treated with stem cell therapy for Feline Kidney Disease.

Dr. Richter explains why this could work for Kitters, Stem cells are cells within your body that are able to turn into any other cell in the body. Kitters has kidney issues, so what weve done is harvested some fat from his abdomen and sent that fat to Vet-Stem in San Diego, and what they do is isolate the stem cells from the fatty tissue. They concentrate them and send them back to us. In the case of an animal with kidney disease, we just give the stem cells intravenously. What that is going to do is begin the healing and rebuilding process.

Nickys film explores the importance of kidneys stating they play a vital role, ridding the body of toxins. As kidney disease progresses scar tissue develops making it harder to filter toxins. Damage to the kidneys makes the animal vulnerable to a number of other health conditions. Unfortunately the disease usually goes undiagnosed given that the symptoms of the disease often do not show until 2/3 of the kidneys are damaged.

Kitters own stem cells were used with the hope of repairing his damaged tissue Dr. Richter goes on, The nice thing about stem cells is that there is no issue of tissue rejection, since it is Kitters own stem cells. Additionally, if there is anything else going on in his body beyond the kidneys its going to address that as well. So, it is a really wonderful systemic treatment.

To find out more or view the special interest piece by Nicky Sims, Stem Cell Therapy for Feline Kidney Disease, visit this link.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Go here to see the original:
Stem Cell Therapy for Feline Kidney Disease, a Video Testimonial by a Pleased Pet Owner Gives Hope for Cats Suffering ...